PD-1 gene polymorphisms and thyroid expression of PD-1 ligands differ between Graves’ and Hashimoto’s diseases

References

• Menconi F, Oppenheim YL, Tomer Y. Graves’ disease. In: Shoenfeld Y, Cervera R,Gershwin ME, editor. Diagnostic criteria in autoimmune diseases. Totowa (NJ): Humana Press; 2008. p. 231–235.
   Google Scholar
• Weetman AP. Chronic autoimmune thyroiditis. In: Braverman L, Utiger R, editor. The thyroid: a fundamental and clinical text. Philadelphia (PA): Lippincott Williams & Wilkins; 2000. p. 721–732.
   Google Scholar
• Laurberg P, Wallin G, Tallstedt L, et al. TSH-receptor autoimmunity in graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158(1):69–75.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006;27(4):195–201.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–242.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Wang W, Lau R, Yu D, et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(hi) regulatory T cells. Int Immunol. 2009;21(9):1065–1077.
   PubMed Web of Science ®Google Scholar
• Wang J, Yoshida T, Nakaki F, et al. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA. 2005;102(33):11823–11828.
   PubMed Web of Science ®Google Scholar
• Waeckerle-Men Y, Starke A, Wüthrich RP. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells. Nephrol Dial Transplant. 2007;22(6):1527–1536.
   PubMed Web of Science ®Google Scholar
• Stanciu LA, Bellettato CM, Laza-Stanca V, et al. Expression of programmed death-1 ligand (PD-L) 1, PD-L2, B7-H3, and inducible costimulator ligand on human respiratory tract epithelial cells and regulation by respiratory syncytial virus and type 1 and 2 cytokines. J Infect Dis. 2006;193(3):404–412.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Kawano S, Hatachi S, et al. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjogren's syndrome. J Rheumatol. 2005;32(11):2156–2163.
   PubMed Web of Science ®Google Scholar
• Kanai T, Totsuka T, Uraushihara K, et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol. 2003;171(8):4156–4163.
   PubMed Web of Science ®Google Scholar
• Sakthivel P, Ramanujam R, Wang XB, et al. Programmed death-1: from gene to protein in autoimmune human myasthenia gravis. J Neuroimmunol. 2008;193(1–2):149–155.
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Jie X, Ihara K, et al. Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with type 1 diabetes. Diabet Med. 2006;23(10):1145–1150.
   PubMed Web of Science ®Google Scholar
• Kong EK, Prokunina-Olsson L, Wong WH, et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum. 2005;52(4):1058–1062.
   PubMedGoogle Scholar
• Liu X, Hu LH, Li YR, et al. Programmed cell death 1 gene polymorphisms is associated with ankylosing spondylitis in Chinese Han population. Rheumatol Int. 2011;31(2):209–213.
   PubMed Web of Science ®Google Scholar
• Ishizaki Y, Yukaya N, Kusuhara K, et al. PD1 as a common candidate susceptibility gene of subacute sclerosing panencephalitis. Hum Genet. 2010;127(4):411–419.
   PubMed Web of Science ®Google Scholar
• Kasamatsu T, Ino R, Takahashi N, et al. PDCD1 and CTLA4 polymorphisms affect the susceptibility to, and clinical features of, chronic immune thrombocytopenia. Br J Haematol. 2018;180(5):705–714.
   PubMed Web of Science ®Google Scholar
• Nakano A, Watanabe M, Iida T, et al. Apoptosis-induced decrease of intrathyroidal CD4(+)CD25(+) regulatory T cells in autoimmune thyroid diseases. Thyroid. 2007;17(1):25–31.
   PubMed Web of Science ®Google Scholar
• Bartosinska J, Zakrzewska E, Krol A, et al. Differential expression of programmed death 1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis and psoriatic arthritis. Pol Arch Intern Med. 2017;127(12):815–822.
   PubMedGoogle Scholar
• Dolff S, Quandt D, Feldkamp T, et al. Increased percentages of PD-1 on CD4+ T cells is associated with higher INF-gamma production and altered IL-17 production in patients with systemic lupus erythematosus. Scand J Rheumatol. 2014;43(4):307–313.
   PubMed Web of Science ®Google Scholar
• Wang Y, Pang N, Wang X, et al. Percentages of PD-1 + CD4 + T cells and PD-L1 + DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia. Hum Vaccin Immunother. 2018;14(4):832–838.
   PubMed Web of Science ®Google Scholar
• Figueroa-Vega N, Alfonso-Perez M, Benedicto I, et al. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis. J Clin Endocrinol Metab. 2010;95(2):953–962.
   PubMed Web of Science ®Google Scholar
• Kinter AL, Godbout EJ, McNally JP, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008;181(10):6738–6746.
   PubMed Web of Science ®Google Scholar
• Phenekos C, Vryonidou A, Gritzapis AD, et al. Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto’s thyroiditis (Th1) and Graves’ disease (Th2). Neuroimmunomodulation. 2004;11(4):209–213.
   PubMed Web of Science ®Google Scholar
• Iwatani Y, Gerstein HC, Iitaka M, et al. Thyrocyte HLA-DR expression and interferon-gamma production in autoimmune thyroid disease. J Clin Endocrinol Metab. 1986;63(3):695–708.
   PubMed Web of Science ®Google Scholar
• Salmaso C, Olive D, Pesce G, et al. Costimulatory molecules and autoimmune thyroid diseases. Autoimmunity. 2002;35(3):159–167.
   PubMed Web of Science ®Google Scholar
• Alvarez-Sierra D, Marin-Sanchez A, Ruiz-Blazquez P, et al. Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J Autoimmun. 2019;103:102285.
   PubMed Web of Science ®Google Scholar
• Battifora M, Pesce G, Paolieri F, et al. B7.1 costimulatory molecule is expressed on thyroid follicular cells in Hashimoto’s thyroiditis, but not in graves’ disease. J Clin Endocrinol Metab. 1998;83(11):4130–4139.
   PubMed Web of Science ®Google Scholar
• Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA. 2003;100(9):5336–5341.
   PubMed Web of Science ®Google Scholar
• Nanba T, Watanabe M, Inoue N, et al. Increases of the Th1/Th2 cell ratio in severe Hashimoto’s disease and in the proportion of Th17 cells in intractable graves’ disease. Thyroid. 2009;19(5):495–501.
   PubMed Web of Science ®Google Scholar
• Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111–122.
   PubMed Web of Science ®Google Scholar
• Iwatani Y, Amino N, Miyai K. Peripheral self-tolerance and autoimmunity: the protective role of expression of class II major histocompatibility antigens on non-lymphoid cells. Biomed Pharmacother. 1989;43(8):593–605.
   PubMed Web of Science ®Google Scholar